fluorouracil has been researched along with Anoxemia in 25 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5-Fluorouracil (5-FU) is an important chemotherapeutic agent for the systemic treatment of colorectal cancer (CRC), but its effectiveness against CRC is limited by increased 5-FU resistance caused by the hypoxic tumor microenvironment." | 7.91 | Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer. ( Kim, CW; Kim, HG; Lee, DH; Lee, JS; Oh, ET; Park, HJ, 2019) |
| "Radiosensitization by vorinostat under hypoxia was studied in four colorectal carcinoma cell lines and in one colorectal carcinoma xenograft model by analysis of clonogenic survival and tumor growth delay, respectively." | 7.78 | Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. ( Flatmark, K; Fleten, KG; Furre, T; Hektoen, HH; Kristian, A; Ree, AH; Saelen, MG, 2012) |
| "The antitumor effect and bone marrow toxicity of 5-fluorouracil (5FU) in combination with the hypoxia-selective cytotoxins NLCQ-1 or tirapazamine (TPZ) were investigated in vivo." | 7.71 | Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine. ( Bloomer, WD; Ji, M; Ji, X; Papadopoulou, MV, 2002) |
| " We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib." | 7.71 | Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002) |
| "Plasma erythropoietin levels during continuous exposure to hypobaric hypoxia in mice with marrow aplasia induced by whole body X-irradiation of 5-fluorouracil injection were higher than in control mice similarly exposed." | 7.66 | Erythropoietin formation during hypoxia in mice with impaired responsiveness to erythropoietin induced by irradiation or 5-fluorouracil injection. ( Barceló, AC; Bozzini, CE, 1982) |
| "Chloroquine (CQ) is an effective and safe antimalarial drug that is also used as a disease-modifying antirheumatic drug." | 5.91 | Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia. ( Ju, S; Jung, Y; Kang, C; Kim, J, 2023) |
| "Avascular-differentiated regions in squamous cell carcinoma offer sanctuary to some hypoxic but viable tumor cells (carbonic anhydrase IX and Ki67 positive) that escape therapy because of limited drug delivery." | 5.32 | Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. ( Azrak, R; Bhattacharya, A; Cao, S; Durrani, FA; Mazurchuk, R; Pendyala, L; Rustum, YM; Slocum, HK; Spernyak, JA; Tóth, K, 2004) |
| " This study aims to investigate the role of the hypoxia-induced miR-675-5p in 5-Fluorouracil (5-FU) resistance on colorectal cancer (CRC) cells." | 4.12 | Mir-675-5p supports hypoxia-induced drug resistance in colorectal cancer cells. ( Alessandro, R; Barreca, MM; Conigliaro, A; Cordaro, A; Corrado, C; Zichittella, C, 2022) |
| " In this context, tumor-associated macrophages (TAM) have been related to chemoresistance to 5-fluorouracil (5-FU), the first-line chemotherapeutic agent used in treating colorectal cancers." | 4.02 | Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer. ( Decaens, T; Gharzeddine, K; Laverriere, MH; Malier, M; Marsili, S; Millet, A; Roth, G; Thomas, F, 2021) |
| "5-Fluorouracil (5-FU) is an important chemotherapeutic agent for the systemic treatment of colorectal cancer (CRC), but its effectiveness against CRC is limited by increased 5-FU resistance caused by the hypoxic tumor microenvironment." | 3.91 | Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer. ( Kim, CW; Kim, HG; Lee, DH; Lee, JS; Oh, ET; Park, HJ, 2019) |
| "Radiosensitization by vorinostat under hypoxia was studied in four colorectal carcinoma cell lines and in one colorectal carcinoma xenograft model by analysis of clonogenic survival and tumor growth delay, respectively." | 3.78 | Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. ( Flatmark, K; Fleten, KG; Furre, T; Hektoen, HH; Kristian, A; Ree, AH; Saelen, MG, 2012) |
| "The antitumor effect and bone marrow toxicity of 5-fluorouracil (5FU) in combination with the hypoxia-selective cytotoxins NLCQ-1 or tirapazamine (TPZ) were investigated in vivo." | 3.71 | Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine. ( Bloomer, WD; Ji, M; Ji, X; Papadopoulou, MV, 2002) |
| " We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib." | 3.71 | Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002) |
| "Plasma erythropoietin levels during continuous exposure to hypobaric hypoxia in mice with marrow aplasia induced by whole body X-irradiation of 5-fluorouracil injection were higher than in control mice similarly exposed." | 3.66 | Erythropoietin formation during hypoxia in mice with impaired responsiveness to erythropoietin induced by irradiation or 5-fluorouracil injection. ( Barceló, AC; Bozzini, CE, 1982) |
| "Chloroquine (CQ) is an effective and safe antimalarial drug that is also used as a disease-modifying antirheumatic drug." | 1.91 | Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia. ( Ju, S; Jung, Y; Kang, C; Kim, J, 2023) |
| "However, chemically induced anoxia induced Ser(392)-site phosphorylation as well as stabilization of both p53 and HIF-1 proteins." | 1.32 | Hypoxia attenuates the p53 response to cellular damage. ( Achison, M; Hupp, TR, 2003) |
| "Avascular-differentiated regions in squamous cell carcinoma offer sanctuary to some hypoxic but viable tumor cells (carbonic anhydrase IX and Ki67 positive) that escape therapy because of limited drug delivery." | 1.32 | Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. ( Azrak, R; Bhattacharya, A; Cao, S; Durrani, FA; Mazurchuk, R; Pendyala, L; Rustum, YM; Slocum, HK; Spernyak, JA; Tóth, K, 2004) |
| "longum accumulated in hypoxic solid tumors." | 1.31 | Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. ( Amano, J; Fujimori, M; Kano, Y; Nakamura, T; Sasaki, T; Taniguchi, S; Yazawa, K, 2002) |
| "Hypoxia in tumors is associated with malignant progression, metastatic spread, and increased resistance to radiotherapy and chemotherapy." | 1.31 | Nitric oxide-mediated regulation of chemosensitivity in cancer cells. ( Adams, MA; Gofton, TE; Graham, CH; Matthews, NE; Maxwell, LR, 2001) |
| "A case of metastatic carcinoid syndrome with hypoxaemia is described." | 1.29 | Intrapulmonary shunting causing hypoxaemia in a case of carcinoid syndrome. ( Bloom, SR; Greaves, JD; Hammond, PJ; Hughes, JM; Hussain, A; Wallis, SC; Young, ET, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.00) | 18.7374 |
| 1990's | 4 (16.00) | 18.2507 |
| 2000's | 8 (32.00) | 29.6817 |
| 2010's | 6 (24.00) | 24.3611 |
| 2020's | 3 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malier, M | 1 |
| Gharzeddine, K | 1 |
| Laverriere, MH | 1 |
| Marsili, S | 1 |
| Thomas, F | 1 |
| Decaens, T | 1 |
| Roth, G | 1 |
| Millet, A | 1 |
| Zichittella, C | 1 |
| Barreca, MM | 1 |
| Cordaro, A | 1 |
| Corrado, C | 1 |
| Alessandro, R | 1 |
| Conigliaro, A | 1 |
| Kang, C | 2 |
| Ju, S | 2 |
| Kim, J | 2 |
| Jung, Y | 2 |
| Kim, HG | 1 |
| Kim, CW | 1 |
| Lee, DH | 1 |
| Lee, JS | 1 |
| Oh, ET | 1 |
| Park, HJ | 1 |
| Li, JQ | 1 |
| Wu, X | 1 |
| Gan, L | 1 |
| Yang, XL | 1 |
| Miao, ZH | 1 |
| Foucher, ED | 1 |
| Ghigo, C | 1 |
| Chouaib, S | 1 |
| Galon, J | 1 |
| Iovanna, J | 1 |
| Olive, D | 1 |
| Limani, P | 1 |
| Linecker, M | 1 |
| Kachaylo, E | 1 |
| Tschuor, C | 1 |
| Kron, P | 1 |
| Schlegel, A | 1 |
| Ungethuem, U | 1 |
| Jang, JH | 1 |
| Georgiopoulou, S | 1 |
| Nicolau, C | 1 |
| Lehn, JM | 1 |
| Graf, R | 1 |
| Humar, B | 1 |
| Clavien, PA | 1 |
| Shah, SM | 1 |
| Drage, MG | 1 |
| Lichtman, AH | 1 |
| Haddad, RI | 1 |
| Saelen, MG | 1 |
| Ree, AH | 1 |
| Kristian, A | 1 |
| Fleten, KG | 1 |
| Furre, T | 1 |
| Hektoen, HH | 1 |
| Flatmark, K | 1 |
| Papadopoulou, MV | 1 |
| Ji, M | 1 |
| Ji, X | 1 |
| Bloomer, WD | 1 |
| Nakamura, T | 1 |
| Sasaki, T | 1 |
| Fujimori, M | 1 |
| Yazawa, K | 1 |
| Kano, Y | 1 |
| Amano, J | 1 |
| Taniguchi, S | 1 |
| Lin, E | 1 |
| Morris, JS | 1 |
| Ayers, GD | 1 |
| Achison, M | 1 |
| Hupp, TR | 1 |
| Bhattacharya, A | 1 |
| Tóth, K | 1 |
| Mazurchuk, R | 1 |
| Spernyak, JA | 1 |
| Slocum, HK | 1 |
| Pendyala, L | 1 |
| Azrak, R | 1 |
| Cao, S | 1 |
| Durrani, FA | 1 |
| Rustum, YM | 1 |
| Kinuya, S | 1 |
| Yokoyama, K | 1 |
| Fukuoka, M | 1 |
| Mori, H | 1 |
| Shiba, K | 1 |
| Watanabe, N | 1 |
| Shuke, N | 1 |
| Michigishi, T | 1 |
| Tonami, N | 1 |
| Lee, CH | 1 |
| Wu, CL | 1 |
| Shiau, AL | 1 |
| Barceló, AC | 1 |
| Bozzini, CE | 1 |
| Hussain, A | 1 |
| Young, ET | 1 |
| Greaves, JD | 1 |
| Hammond, PJ | 1 |
| Hughes, JM | 1 |
| Wallis, SC | 1 |
| Bloom, SR | 1 |
| Ben-Ari, GY | 1 |
| McSheehy, PM | 1 |
| Robinson, SP | 1 |
| Ojugo, AS | 1 |
| Aboagye, EO | 1 |
| Cannell, MB | 1 |
| Leach, MO | 1 |
| Judson, IR | 1 |
| Griffiths, JR | 1 |
| Ehrnrooth, E | 1 |
| von der Maase, H | 1 |
| Sørensen, BS | 1 |
| Poulsen, JH | 1 |
| Horsman, MR | 1 |
| Matthews, NE | 1 |
| Adams, MA | 1 |
| Maxwell, LR | 1 |
| Gofton, TE | 1 |
| Graham, CH | 1 |
| Kaplan, HS | 1 |
| Kelly, JP | 1 |
| Hannam, TW | 1 |
| Giles, GR | 1 |
| Bengmark, S | 1 |
| Puntis, M | 1 |
| Jeppsson, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-12-08 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for fluorouracil and Anoxemia
| Article | Year |
|---|---|
Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle C | 2018 |
1977 Henry H. Janeway lecture: fundamental mechanisms in combined modality therapy of cancer.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Dactinomycin; DNA Repair; DNA, Neoplasm; Electron | 1977 |
23 other studies available for fluorouracil and Anoxemia
| Article | Year |
|---|---|
Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Colorect | 2021 |
Mir-675-5p supports hypoxia-induced drug resistance in colorectal cancer cells.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouraci | 2022 |
Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia.
Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Chloroquine; Colo | 2023 |
Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia.
Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Chloroquine; Colo | 2023 |
Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia.
Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Chloroquine; Colo | 2023 |
Chloroquine prevents hypoxic accumulation of HIF-1α by inhibiting ATR kinase: implication in chloroquine-mediated chemosensitization of colon carcinoma cells under hypoxia.
Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Chloroquine; Colo | 2023 |
Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer.
Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; | 2019 |
Hypoxia induces universal but differential drug resistance and impairs anticancer mechanisms of 5-fluorouracil in hepatoma cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Proliferation; DNA Breaks, Double-Stranded; Dose-Response Re | 2017 |
Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Colonic Neoplasms; Disease Model | 2016 |
Metastatic human papillomavirus-positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread.
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biomarkers, Tumor; Carb | 2012 |
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycy | 2012 |
Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Synergism; Female; Fluoro | 2002 |
Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors.
Topics: Antimetabolites, Antineoplastic; Bifidobacterium; Blotting, Western; Cloning, Molecular; Cytosine De | 2002 |
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Celecoxib; Colorectal Neoplasms; | 2002 |
Hypoxia attenuates the p53 response to cellular damage.
Topics: Apoptosis; Cell Survival; Down-Regulation; Fluorouracil; Humans; Hypoxia; Phosphorylation; Tumor Cel | 2003 |
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, | 2004 |
Anti-angiogenic therapy and chemotherapy affect 99mTc sestamibi and 99mTc-HL91 accumulation differently in tumour xenografts.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Estradiol; Fluorouracil; Hum | 2005 |
Hypoxia-induced cytosine deaminase gene expression for cancer therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Lewis Lung; Cell Line, Tumor; Cytosine Deaminas | 2007 |
Erythropoietin formation during hypoxia in mice with impaired responsiveness to erythropoietin induced by irradiation or 5-fluorouracil injection.
Topics: Animals; Erythrocytes; Erythropoiesis; Erythropoietin; Female; Fluorouracil; Hypoxia; Iron; Mice | 1982 |
Intrapulmonary shunting causing hypoxaemia in a case of carcinoid syndrome.
Topics: Adult; Carcinoid Tumor; Drug Therapy, Combination; Fluorouracil; Humans; Hypoxia; Liver Neoplasms; L | 1994 |
Treatment of abdominal malignancies using total abdominal stop-flow infusion and hypoxic perfusion.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, | 1997 |
Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: a magnetic resonance study in vivo.
Topics: Animals; Biological Transport; Carbon Dioxide; Fibrosarcoma; Fluorouracil; Hydrogen-Ion Concentratio | 1998 |
The ability of hypoxia to modify the gene expression of thymidylate synthase in tumour cells in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Base Sequence; DNA Primers; Drug Resistance; Female; Fluor | 1999 |
Nitric oxide-mediated regulation of chemosensitivity in cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell | 2001 |
The cytocidal action of metronidazole in combination with other antineoplastic agents.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Colonic Neoplasms; D | 1979 |
Hepatic dearterialization in cancer: new perspectives.
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Fluorour | 1986 |